Mesenchymal stem cells as vectors for lung cancer therapy

K.K. Kolluri, Geoff Laurent, S.M. Janes

    Research output: Contribution to journalArticlepeer-review

    29 Citations (Scopus)


    Despite recent advances in treatment, lung cancer accounts for one third of all cancer-related deaths, underlining the need of development of new therapies. Mesenchymal stem cells (MSCs) possess the ability to specifically home into tumours and their metastases. This property of MSCs could be exploited for the delivery of various anti-tumour agents directly into tumours. However, MSCs are not simple delivery vehicles but cells with active physiological process. This review outlines various agents which can be delivered by MSCs with substantial emphasis on TRAIL (tumour necrosis factor-related apoptosis-inducing ligand). Copyright © 2013 S. Karger AG, Basel.
    Original languageEnglish
    Pages (from-to)443-451
    Issue number6
    Publication statusPublished - 2013


    Dive into the research topics of 'Mesenchymal stem cells as vectors for lung cancer therapy'. Together they form a unique fingerprint.

    Cite this